



**GEORGIA MEDICAID FEE-FOR-SERVICE
VITRAKVI PA SUMMARY**

Preferred	Non-Preferred
Vitrakvi (larotrectinib)	N/A

LENGTH OF AUTHORIZATION: 1 year

NOTE: Special consideration given for members who have stage IV advanced metastatic cancer.

PA CRITERIA:

- ❖ Approvable for members with a diagnosis of non-small cell lung cancer (NSCLC) who have a neurotrophic receptor tyrosine kinase (*NTRK*) gene fusion without a known acquired resistance mutation.
- ❖ Approvable for members with a diagnosis of salivary gland cancer, congenital/infantile fibrosarcoma, soft tissue sarcoma (other than angiosarcoma or pleomorphic rhabdomyosarcoma), thyroid cancer or other solid tumor who have a neurotrophic receptor tyrosine kinase (*NTRK*) gene fusion without a known acquired resistance mutation, who have a tumor that is metastatic or who surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or who have progressed following treatment.

EXCEPTIONS:

- Exceptions to these conditions of coverage are considered through the prior authorization process.
- The Prior Authorization process may be initiated by calling **OptumRx at 1-866-525-5827**.

PREFERRED DRUG LIST:

- For online access to the Preferred Drug List (PDL), please go to <http://dch.georgia.gov/preferred-drug-lists>.

PA and APPEAL PROCESS:

- For online access to the PA process, please go to www.dch.georgia.gov/prior-authorization-process-and-criteria and click on Prior Authorization (PA) Request Process Guide.

QUANTITY LEVEL LIMITATIONS:

- For online access to the current Quantity Level Limits (QLL), please go to www.mmis.georgia.gov/portal, highlight Pharmacy and click on [Other Documents](#), then select the most recent quarters QLL List.